{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Karbon G"],"funding":["Austrian Science Fund FWF"],"pagination":["1151"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8668920"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(12)"],"pubmed_abstract":["Breast cancer (BC) treatment frequently involves microtubule-targeting agents (MTAs), such as paclitaxel, that arrest cells in mitosis. Sensitivity to MTAs is defined by a subset of pro- and anti-apoptotic BCL2 family proteins controlling mitochondrial apoptosis. Here, we aimed to determine their prognostic value in primary tumour samples from 92 BC patients. Our analysis identified high NOXA/PMAIP mRNA expression levels as an independent prognostic marker for improved relapse-free survival (RFS) and overall survival (OS) in multivariate analysis in BC patients, independent of their molecular subtype. Analysis of available TCGA datasets of 1060 BC patients confirmed our results and added a clear predictive value of NOXA mRNA levels for patients who received MTA-based therapy. In this TCGA "],"journal":["Cell death & disease"],"pubmed_title":["The BH3-only protein NOXA serves as an independent predictor of breast cancer patient survival and defines susceptibility to microtubule targeting agents."],"pmcid":["PMC8668920"],"funding_grant_id":["P 29499","P-29499","I-3271"],"pubmed_authors":["Parson W","Villunger A","Karbon G","Haschka MD","Soratroi C","Rocamora-Reverte L","Hackl H","Fiegl H"],"additional_accession":[]},"is_claimable":false,"name":"The BH3-only protein NOXA serves as an independent predictor of breast cancer patient survival and defines susceptibility to microtubule targeting agents.","description":"Breast cancer (BC) treatment frequently involves microtubule-targeting agents (MTAs), such as paclitaxel, that arrest cells in mitosis. Sensitivity to MTAs is defined by a subset of pro- and anti-apoptotic BCL2 family proteins controlling mitochondrial apoptosis. Here, we aimed to determine their prognostic value in primary tumour samples from 92 BC patients. Our analysis identified high NOXA/PMAIP mRNA expression levels as an independent prognostic marker for improved relapse-free survival (RFS) and overall survival (OS) in multivariate analysis in BC patients, independent of their molecular subtype. Analysis of available TCGA datasets of 1060 BC patients confirmed our results and added a clear predictive value of NOXA mRNA levels for patients who received MTA-based therapy. In this TCGA ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Dec","modification":"2026-05-09T11:42:54.15Z","creation":"2022-02-11T13:59:08.11Z"},"accession":"S-EPMC8668920","cross_references":{"pubmed":["34903710"],"doi":["10.1038/s41419-021-04415-y"]}}